Aktuellt
SENASTE
Redeye leaves its initial comments in response to InDex Pharmaceuticals' announcement regarding the discontinuation of the Phase III program CONCLUDE, which introduces uncertainty regarding the company's future. We anticipate a significant decline in the share today as cobitolimod was the primary value driver in the company; nevertheless, we believe that the cash position (SEK 412.5m at the end of Q2) will help mitigate the impact.
LÄS MER
